918331-98-3

Upstream product

• 350-28-7 3-fluoro-4-methyl-benzoic acid 
• 861905-94-4 3-fluoro-5-iodo-4-methylbenzoic acid 

Downstream Products

• 585544-31-6 N-cyclopropyl-3-fluoro-5-iodo-4-methylbenzamide 
• 861905-38-6 N-ethyl-3-fluoro-5-iodo-4-methylbenzamide 
• 917223-84-8 3-fluoro-5-iodo-N-3-isoxazolyl-4-methylbenzamide 
• 585544-29-2 N-cyclopropyl-5-fluoro-4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzamide 
• 861905-22-8 methyl 3-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 917223-86-0 {3-fluoro-5-[(3-isoxazolylamino)carbonyl]-2-methylphenyl}boronic acid 
• 917223-88-2 methyl 3-(5-{[(2,2-dimethylpropyl)amino]carbonyl}-2-pyridinyl)-5-fluoro-4-methylbenzoate 
• 917223-81-5 3-(5-{[(2,2-dimethylpropyl)amino]carbonyl}-2-pyridinyl)-5-fluoro-4-methylbenzoic acid 
• 917223-75-7 N-(2,2-dimethylpropyl)-6-{3-fluoro-5-[(3-isoxazolylamino)carbonyl]-2-methylphenyl}-3-pyridinecarboxamide 
• 861905-21-7 methyl 3-fluoro-5-iodo-4-methylbenzoate 
• 861905-45-5 N-(1-ethyl-1H-pyrazol-5-yl)-3-fluoro-5-iodo-4-methylbenzamide 
• 861905-50-2 3-fluoro-5-iodo-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)benzamide 

Relevant academic research and scientific papers

BENZAMIDE DERIVATIVE

The present invention relates to a benzamide derivative of general formula I, a drug composition containing same and a use thereof as a drug, wherein the definitions of R1, Z and Q are as described in the description.

NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to processes for their preparation, to pharmaceutical compositions comprising them, and to their use in therapy.

p38α mitogen-activated protein kinase inhibitors: Optimization of a series of biphenylamides to give a molecule suitable for clinical progression

p38α MAP kinase is a key anti-inflammatory target for rheumatoid arthritis, influencing biosynthesis of pro-inflammatory cytokines TNFα and IL-1β at a translational and transcriptional level. In this paper, we describe how we have optimized a series of no

NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS

New bicyclic derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.

NOVEL COMPOUNDS

Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use use in therapy as CSBP/RK/p38 kinase inhibitors.

N-(2, 2-DIMETHYLPROPYL) -6- (3-FLUORO-5- ( (3-ISOXAZOLYLAMINO) CARBONYL) -2-METHYLPHENY L) -3-PYRIDINECARBOXAMIDE

The present invention relates to a novel compound, processes for its preparation, compositions comprising the same and its use in the treatment of condition or diseases mediated by p38 kinase activity.

3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.